Key points are not available for this paper at this time.
To the Editor:The recent regulatory approval of two menin inhibitors, revumenib and ziftomenib, for treatment of relapsed and/or refractory acute leukemia has introduced a new class of targeted the...
Markosian et al. (Wed,) studied this question.